Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Revenue Drivers
VRTX logo

Vertex's Q3 Revenues Hit $3.1B, Up 11% on CF Strength and New Launches

VRTX10-QFiling Date: 11/4/2025
Vertex Pharmaceuticals Incorporated
Description

What this story covers

Vertex Pharmaceuticals reported Q3 2025 revenues of $3.1B, up 11%, driven by Trikafta ($2.7B) and launches of Alyftrek ($247M) and Journavx ($20M). Pipeline advances in CF, gene editing, pain, diabetes, and kidney disease, backed by $12B cash and strategic deals, highlight diversification amid stable CF dominance.

Story snapshot

CompanyVertex Pharmaceuticals Incorporated
TickerVRTX
VariantStandard detailed
Duration11:52
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000875320-25-000232

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in